• Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)

      Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Abraham, George M.; Jokela, Janet A.; Forciea, Mary Ann; Miller, Matthew C.; Humphrey, Linda L. (2021-02-09)
      Practice points for clinicians developed by the American College of Physicians addressing these questions: What are the effectiveness and harms of remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19)? Do effectiveness and harms in hospitalized patients with COVID-19 vary by symptom duration, disease severity, and treatment duration?
    • Update Alert: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)

      Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Abraham, George M.; Jokela, Janet A.; Miller, Matthew C.; Forciea, Mary Ann.; Humphrey, Linda L. (2021-09-01)
      This is an update of the American College of Physicians' living, rapid practice points about using remdesivir for treatment of COVID-19, which is based on an updated systematic review done through 10 May 2021. The evidence update identified 1 new study that could inform Practice Point 1. No new studies were identified as supporting evidence for Practice Points 2 or 3. The new study did not have an effect on our prior conclusions and resulted in no changes to the practice points (see the next section and the Supplement). We have changed the term mechanical ventilation to invasive ventilation to better reflect most of the patient populations informing the practice points. We define invasive ventilation as administering supplemental oxygen with positive pressure to the lungs via an endotracheal or tracheostomy tube. The Supplement summarizes the evidence, evidence gaps, and clinical considerations.